EMA Recommends Granting a Marketing Authorisation for Hybrid Thalidomide
Thalidomide Lipomed is intended for the treatment of multiple myeloma
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
Sacituzumab Govitecan Demonstrates Significant Improvement in Survival in Heavily Pretreated, Locally Recurrent Inoperable, or Metastatic HR-positive, HER2-negative Breast Cancer
Primary results of the TROPiCS-02 study
FDA Grants Accelerated Approval to fam-Trastuzumab Deruxtecan-nxki for HER2-Mutated NSCLC
FDA also approved companion diagnostics for selection of patients
EMA Recommends Granting a Marketing Authorisation for Celdoxome Pegylated Liposomal
It is a hybrid medicine of Adriamycin, but available in a pegylated liposomal formulation
Long-Term Outcomes Suggest a Sustained Clinical Benefit to Metastasis-Directed Treatment Over Observation in Oligometastatic Castration-Sensitive Prostate Cancer
Long-term follow-up findings from STOMP and ORIOLE and analysis of genomic predictors of response
Associations Between Genomic Features and Response to Neoadjuvant Treatment in a Large Cohort of Patients with Rectal Cancer
A comprehensive analysis highlights clinically relevant associations between genomic, transcriptomic features, immunologic profiles and treatment outcomes
FDA Approves Capmatinib for Metastatic NSCLC
Conversion from accelerated to regular approval was based on data from additional patients in the GEOMETRY mono-1 study
Rapid, Robust and Durable Antitumour Activity of Pralsetinib in Patients with Different RET Fusion Positive Solid Tumours
ARROW validates RET as a tissue-agnostic target
EMA Recommends Extension of Therapeutic Indications for Selpercatinib
It adopted an extension of indication for the treatment of advanced RET-mutated medullary thyroid cancer
FDA Approves fam-Trastuzumab Deruxtecan-nxki for HER2-Low Breast Cancer
Evidence for efficacy is based on the results from the DESTINY-Breast04 study
TIL Densities Association with Disease-Free Survival Differs by Primary Tumour Sidedness in Stage III Colon Cancer
Findings from the NCCTG N0147 Alliance study analysis
Teclistamab Results in a High Rate of Deep and Durable Response in Patients with Triple-Class–Exposed Relapsed or Refractory Multiple Myeloma
Findings from the MajesTEC-1 study